Home - Medical Policies - Alabama
- Advanced Imaging
- Autism Spectrum Mandate
- Behavioral Health
- Blue Advantage Policies
- Chronic Condition Management
- Genetic Testing
- Hemophilia Drugs
- Medical Policies
- Provider-Administered Drug Policies (Excluding Oncology)
- Provider-Administered Oncology Drug Policies
- Radiation Therapy
- Self-Administered Drug Policies
- Transgender Services
Draft Genetic Testing Policies
Effective January 1, 2021, Blue Cross and Blue Shield of Alabama will partner with AIM Specialty Health®, an independent company, to administer genetic testing solutions for our customers.
AIM is our business associate and is an independent company that provides diagnostic testing, information and services. AIM has agreed to follow Blue Cross' privacy and security policies regarding the confidentiality and protection of your personal health information.
Genetic Testing
Genetic Testing
How to Submit Comments on Draft Policies
To ensure that the development of medical policies occurs through an open, collaborative process, we welcome comments about medical policies that are in the draft stage.
Participating providers and other providers are invited to submit scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to these draft policies for consideration. We accept comments for 45 days from the posting date listed on the draft policy document.
Note: Coverage is subject to member's specific benefits. Group-specific policies will supersede these policies when applicable. Please refer to member's benefit plan.
Participating providers can comment on draft policies online or via mail or fax:
- Complete our medical policy feedback form
- Send comments by mail or fax to:
Blue Cross Blue Shield of Alabama
Attn: Health Management - Medical Policy
P.O. Box 995
Birmingham, AL 35298-0001
Fax: 205-220-0878